You are seeing these quotes based on previous browsing related to sectors such as
| Latest | Forecast | |
|---|---|---|
| Div Yield | 5.7% | 4.0% |
| Div Cover | 1.4 | 2.6 |
| Op Mrgn | 18.2% | 27.9% |
| ROCE | 68.3% |
| Latest | Forecast | |
|---|---|---|
| P/E | 12.5 | 0.0 |
| PEG | -5.4 | 1.4 |
| Price / Revenue | 1.7 | 2.0 |
| Price / Book value | 2.7 |
| Latest | Forecast | |
|---|---|---|
| Revenue | 0.0% | -21.6% |
| PBT | -21.9% | n/a |
| EPS | -2.3% | 14.1% |
| DPS | 0.0% | -1.4% |
| Year Ending | Revenue (£m) |
Pre-tax (£m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 2018-12-31 | 30,821.00 | 4,800.00 | 119.40p | 15.6 | 2.3 | 7% | 80.00p | 4.3% |
| 2019-12-31 | 33,754.00 | 6,221.00 | 123.90p | 17.9 | 4.8 | 4% | 80.00p | 3.6% |
| 2020-12-31 | 34,099.00 | 6,968.00 | 115.90p | 14.5 | 0.9 | 17% | 80.00p | 4.8% |
| 2021-12-31 | 34,114.00 | 5,442.00 | 113.20p | 17.7 | -7.6 | -2% | 80.00p | 4.0% |
| GSK plans return of HQ to central London in 2024 Sharecast News | 12 Dec |
|---|---|
| GSK shares jump as court dismisses Zantac claims Sharecast News | 07 Dec |
| EU validates market application for GSK blood cancer drug Sharecast News | 02 Dec |
| Director/PDMR Shareholding | 18-Jan-23 23:59 |
|---|---|
| Director/PDMR Shareholding | 18-Jan-23 00:00 |
| Director/PDMR Shareholding | 16-Jan-23 23:58 |
| Director/PDMR Shareholding | 13-Jan-23 23:59 |
| Director/PDMR Shareholding | 12-Jan-23 23:58 |